IN2014CN02315A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN02315A IN2014CN02315A IN2315CHN2014A IN2014CN02315A IN 2014CN02315 A IN2014CN02315 A IN 2014CN02315A IN 2315CHN2014 A IN2315CHN2014 A IN 2315CHN2014A IN 2014CN02315 A IN2014CN02315 A IN 2014CN02315A
- Authority
- IN
- India
- Prior art keywords
- proliferation
- formula
- carcinoma cells
- mucoepidermoid carcinoma
- imidazoquinolines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161541758P | 2011-09-30 | 2011-09-30 | |
| US201261660377P | 2012-06-15 | 2012-06-15 | |
| PCT/US2012/057480 WO2013049300A1 (en) | 2011-09-30 | 2012-09-27 | Method of treating mucoepidermoid carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN02315A true IN2014CN02315A (instruction) | 2015-06-19 |
Family
ID=47016842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2315CHN2014 IN2014CN02315A (instruction) | 2011-09-30 | 2012-09-27 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140243396A1 (instruction) |
| EP (1) | EP2760445A1 (instruction) |
| JP (1) | JP2014532057A (instruction) |
| KR (1) | KR20140069038A (instruction) |
| CN (1) | CN103906515A (instruction) |
| AU (1) | AU2012316020A1 (instruction) |
| BR (1) | BR112014005730A2 (instruction) |
| CA (1) | CA2848065A1 (instruction) |
| EA (1) | EA201490725A1 (instruction) |
| IN (1) | IN2014CN02315A (instruction) |
| MX (1) | MX2014003873A (instruction) |
| WO (1) | WO2013049300A1 (instruction) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2986359A1 (en) | 2015-05-20 | 2016-11-24 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
| US10441584B2 (en) | 2016-11-23 | 2019-10-15 | Novartis Ag | Methods of enhancing immune response |
| US20200362303A1 (en) * | 2017-11-30 | 2020-11-19 | Kyoto University | Maintenance-and-amplification method and differentiation induction method for primordial germ cells/primordial germ cell-like cells |
| US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
| CN108578016B (zh) | 2018-04-26 | 2020-09-08 | 赛诺医疗科学技术股份有限公司 | 一种经心尖植入式二尖瓣瓣膜装置 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090298864A1 (en) | 2005-04-11 | 2009-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for Treating Mild Cognitive Impairment |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| RS53335B (en) * | 2006-11-20 | 2014-10-31 | Novartis Ag | CRYSTAL MONOTOSYLATE SO 2-METHYL-2- [4- (3-METHYL-2-OXO-8-HINOLIN-3-IL-2,3-Dihydro-imidazo [4,5-C] HINOLIN-1-IL) - Phenyl] -PROPIONITRILA |
| WO2009052467A1 (en) * | 2007-10-19 | 2009-04-23 | Board Of Regents Of The University Of Texas System | Methods of identifying pi-3-kinase inhibitor resistance |
| US20090192220A1 (en) * | 2007-11-19 | 2009-07-30 | Ore Pharmaceuticals Inc. | Treatment for solid tumors |
| WO2009155659A1 (en) * | 2008-06-27 | 2009-12-30 | The University Of Queensland | Combination therapy |
| US8476431B2 (en) * | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| WO2011133668A2 (en) * | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
| WO2012068487A1 (en) * | 2010-11-18 | 2012-05-24 | Synta Pharmaceuticals Corp. | Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status |
-
2012
- 2012-09-27 CN CN201280047473.6A patent/CN103906515A/zh active Pending
- 2012-09-27 WO PCT/US2012/057480 patent/WO2013049300A1/en active Application Filing
- 2012-09-27 IN IN2315CHN2014 patent/IN2014CN02315A/en unknown
- 2012-09-27 BR BR112014005730A patent/BR112014005730A2/pt not_active IP Right Cessation
- 2012-09-27 US US14/347,961 patent/US20140243396A1/en not_active Abandoned
- 2012-09-27 KR KR1020147007973A patent/KR20140069038A/ko not_active Withdrawn
- 2012-09-27 AU AU2012316020A patent/AU2012316020A1/en not_active Abandoned
- 2012-09-27 CA CA2848065A patent/CA2848065A1/en not_active Abandoned
- 2012-09-27 EA EA201490725A patent/EA201490725A1/ru unknown
- 2012-09-27 EP EP12772178.5A patent/EP2760445A1/en not_active Withdrawn
- 2012-09-27 MX MX2014003873A patent/MX2014003873A/es unknown
- 2012-09-27 JP JP2014533710A patent/JP2014532057A/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN103906515A (zh) | 2014-07-02 |
| AU2012316020A1 (en) | 2013-05-09 |
| US20140243396A1 (en) | 2014-08-28 |
| EP2760445A1 (en) | 2014-08-06 |
| MX2014003873A (es) | 2014-05-28 |
| JP2014532057A (ja) | 2014-12-04 |
| WO2013049300A1 (en) | 2013-04-04 |
| CA2848065A1 (en) | 2013-04-04 |
| KR20140069038A (ko) | 2014-06-09 |
| EA201490725A1 (ru) | 2014-11-28 |
| BR112014005730A2 (pt) | 2017-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013009256A (es) | Metodo para inhibir las celulas tumorales hamartoma. | |
| MX349159B (es) | Derivados deuterados de ivacaftor. | |
| PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| MY185103A (en) | Bezylamine derivatives as inhibitors of plasma kallikrein | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| IN2015DN01156A (instruction) | ||
| PH12013500473A1 (en) | Triazine-oxadiazoles | |
| IN2014MN01755A (instruction) | ||
| MY191358A (en) | Triazolopyrazines as brd4 inhibitors for use in the treatment of cancer | |
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| IN2014KN00769A (instruction) | ||
| PH12013501600A1 (en) | Novel heterocyclic derivatives | |
| NZ700283A (en) | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors | |
| IN2015DN01119A (instruction) | ||
| NZ700612A (en) | Methods and compositions for treating ewings sarcoma family of tumors | |
| MX2015008187A (es) | Inhibidores de alk deuterados. | |
| PH12013501591A1 (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation | |
| PH12013501574A1 (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation | |
| MX2011011083A (es) | Compuestos heterociclicos como inhibidores de mek. | |
| IN2015DN03854A (instruction) | ||
| MX361458B (es) | Compuestos de pirimido-piridazinona y uso de los mismos. | |
| MX2013008340A (es) | Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer. | |
| IN2014CN02315A (instruction) | ||
| IN2014DN00123A (instruction) | ||
| NZ707773A (en) | Methods of treating liver diseases |